Navigation Links
Drug Safety Center Update: Employee Alleges Actos Maker Valued Sales Over Safety
Date:3/21/2013

Philadelphia, PA (PRWEB) March 21, 2013

The medication safety advocates at DrugRisks.com are announcing updated information on the site for patients who have taken the diabetes drug Actos. In an ongoing trial over Actos bladder cancer side effects*, a former employee recently alleged in testimony that drug maker Takeda put profit concerns over safety.

DrugRisks was created to provide those taking popular prescription drugs with the latest safety alerts, recalls, studies and legal news. Visitors can determine if other patients are experiencing similar side effects and decide if they need legal advice for current litigation.

Health experts with the FDA** and European Medicines Agency*** have warned patients that long-term use of Actos may be linked to increased risks of bladder cancer. The drug has also been banned in France and Germany****.

The maker of Actos, Takeda Pharmaceuticals, now faces Actos lawsuits from as many as 3,000 patients over bladder cancer*****. Over 1,200 of these have been consolidated in a special multi-district federal court in Louisiana, while others are pending in California.

DrugRisks has added information showing the first Actos lawsuit trial in California* began this month for a man dying of bladder cancer*****. Also, a former pharmacologist for Takeda testified that company emails suggested they were more concerned with continued sales of the drug rather than the safety of patients*****.

Although trials have begun, lawyers are still helping those diagnosed with bladder cancer after taking Actos file claims. Anyone affected is urged to contact the DrugRisks Safety Center or speak with a lawyer about their legal rights as soon as possible.

Due to the specialized nature of drug injury litigation against large pharmaceutical companies, DrugRisks only recommends lawyers and law firms who have already handled Actos lawsuits.
Visit http://www.DrugRisks.com today for more information on Actos bladder cancer research, side effects and litigation news, or to speak with a lawyer.

*Cooper v. Takeda Pharmaceuticals America, Inc., CGC-12-518535, California Superior Court (Los Angeles)
**http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm
***http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/public_health_alerts/2011/07/human_pha_detail_000033.jsp&mid=WC0b01ac058001d126&source=homeMedSearch&category=human
****cbsnews.com/8301-504763_162-20070492-10391704.html
*****bloomberg.com/news/2013-03-05/takeda-put-actos-sales-ahead-of-user-safety-witness-says.html

Read the full story at http://www.prweb.com/releases/actos-lawsuit/actos-lawsuits/prweb10547940.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. New ASTRO white paper recommends peer review to increase quality assurance and safety
2. Studies for approval of new drugs have insufficient patients to evaluate safety
3. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
4. New Guidelines Raise Safety Bar on Concussions
5. Report: Communications technology among tools needed to aid miner safety
6. The Healthy Facilities Institute (HFI) Forms Educational Partnership with the National Floor Safety Institute (NFSI)
7. ERs Not Doing Enough to Educate Parents on Car-Seat Safety: Study
8. Space Heater Safety Tips Can Help Prevent Burns, Fires
9. Internet searches can identify drug safety issues well ahead of public alerts
10. Emergency departments not doing enough to educate parents about car seat safety
11. Report Details Steps to Boost Patient Safety
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... SALT LAKE CITY, UTAH (PRWEB) , ... April ... ... Josée Côté as Account Manager for the North East region. Côté has 20+ ... operations and consulting. Prior to Phytomer, Côté worked with an array of high-end ...
(Date:4/28/2017)... ... April 28, 2017 , ... Rob Lowe is a popular actor that has ... presence to an educational purpose as the host of the “Informed” series. The program ... a recent episode, the series focuses on thyroid cancer. , Although thyroid cancer is ...
(Date:4/27/2017)... , ... April 27, 2017 , ... ... Insights in Incentives, Rewards, and Recognition: A Nudge Guide," a groundbreaking analysis of ... field. Offering practical takeaways to apply immediately to IRR programs, the report highlights ...
(Date:4/27/2017)... Neb. (PRWEB) , ... April 27, 2017 , ... ... was named the 2017 North American CAREGiverSM of the Year for her extraordinary ... selects one of its 60,000 North American professional caregivers for the prestigious award ...
(Date:4/27/2017)... GA (PRWEB) , ... April 27, 2017 , ... Are ... a tragic spike in water-related accidents and drownings during the summer. While most of ... is that these situations occur every day. Very few people are taking the time ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... LUND, Sweden , April 20, 2017 /PRNewswire/ ... OTCQX: NEVPF) ("NeuroVive") today announced positive preclinical ... company,s preclinical compound for non-alcoholic steatohepatitis (NASH), ... NV556 has previously ... STAM™ NASH model. Today, NeuroVive,s scientists present ...
(Date:4/19/2017)... April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) ... & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... , Chief Executive Officer of the Company is scheduled to present ... Richard Bear and the Chairman of the Board, Tony ... ...
Breaking Medicine Technology: